AU2004217433A1 - Vectors used to create hybrid constant regions - Google Patents

Vectors used to create hybrid constant regions Download PDF

Info

Publication number
AU2004217433A1
AU2004217433A1 AU2004217433A AU2004217433A AU2004217433A1 AU 2004217433 A1 AU2004217433 A1 AU 2004217433A1 AU 2004217433 A AU2004217433 A AU 2004217433A AU 2004217433 A AU2004217433 A AU 2004217433A AU 2004217433 A1 AU2004217433 A1 AU 2004217433A1
Authority
AU
Australia
Prior art keywords
constant region
region
light chain
chain constant
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004217433A
Other languages
English (en)
Inventor
Katherine S. Bowdish
Shana Frederickson
Toshiaki Maruyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2004217433A1 publication Critical patent/AU2004217433A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2004217433A 2003-03-04 2004-03-04 Vectors used to create hybrid constant regions Abandoned AU2004217433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45182003P 2003-03-04 2003-03-04
US60/451,820 2003-03-04
PCT/US2004/006571 WO2004078937A2 (en) 2003-03-04 2004-03-04 Vectors used to create hybrid constant regions

Publications (1)

Publication Number Publication Date
AU2004217433A1 true AU2004217433A1 (en) 2004-09-16

Family

ID=32962642

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004217433A Abandoned AU2004217433A1 (en) 2003-03-04 2004-03-04 Vectors used to create hybrid constant regions

Country Status (6)

Country Link
US (1) US20070009957A1 (enExample)
EP (1) EP1606387A4 (enExample)
JP (1) JP2006520610A (enExample)
AU (1) AU2004217433A1 (enExample)
CA (1) CA2517519A1 (enExample)
WO (1) WO2004078937A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7427665B2 (en) 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6803230B2 (en) 2001-04-27 2004-10-12 Alexion Pharmaceuticals, Inc. Phagemid vectors
US8075884B2 (en) 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
US8986684B2 (en) 2007-07-25 2015-03-24 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
US20110059471A1 (en) * 2008-03-14 2011-03-10 Medinet Co., Ltd. Antibody having an immune-enhancement function
WO2010039900A2 (en) * 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PL3251503T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
JP7627413B2 (ja) * 2020-08-21 2025-02-06 ファチアブジェン インコーポレイテッド ガンマ定常領域（Ｃγ１）とイプシロン定常領域（Ｃε２－４）とが融合された重鎖及び軽鎖の定常領域からなる抗体断片及びその用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US7119248B1 (en) * 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6258529B1 (en) * 1994-12-01 2001-07-10 Oravax, Inc. PCR amplification of rearranged genomic variable regions of immunoglobulin genes
WO1997042329A1 (en) * 1996-05-04 1997-11-13 Zeneca Limited Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
IL155977A0 (en) * 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
EP2339035A1 (en) * 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
US6803230B2 (en) * 2001-04-27 2004-10-12 Alexion Pharmaceuticals, Inc. Phagemid vectors
DE60226253T2 (de) * 2001-06-28 2009-05-14 Kyowa Hakko Kogyo Co., Ltd. Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers

Also Published As

Publication number Publication date
US20070009957A1 (en) 2007-01-11
JP2006520610A (ja) 2006-09-14
WO2004078937A2 (en) 2004-09-16
CA2517519A1 (en) 2004-09-16
WO2004078937A3 (en) 2005-12-22
EP1606387A2 (en) 2005-12-21
EP1606387A4 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
US20070009957A1 (en) Vectors used to create hybrid constant regions
AU2002360068B2 (en) Method for cloning of variable domain sequences
AU766253B2 (en) Modulation of polypeptide display on modified filamentous phage
EP0589877B2 (en) METHODS FOR PRODUCING FUNCTIONAL, SINGLE-CHAIN Fv ANTIBODY FRAGMENTS ON THE SURFACE OF BACTERIOPHAGE PARTICLES
USRE42130E1 (en) Phagemid vectors
CN102770555A (zh) 改善的细菌膜蛋白分泌
EP3440208B1 (en) Vectors for cloning and expression of proteins, methods and applications thereof
AU2003253193B2 (en) Novel tricistronic vectors and uses therefor
US11479879B2 (en) Triple vector for expressing antibody molecules in full therapeutic format
AU2010322202B2 (en) Display of disulfide linked dimeric proteins on filamentous phage
JP2012503983A (ja) 適合性ディスプレイベクター系
JP2012503982A (ja) 適合性ディスプレイベクター系
KR20220026869A (ko) 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
CA3038593C (en) Triple vector for expressing antibody molecules in full therapeutic format
US6440700B1 (en) Method of combinatorial protein synthesis based on ribosomal frameshifting
WO2003097796A2 (en) T7 bacteriophage display of fabs
WO2002046436A9 (en) Plasmid vectors
HK1060591A (en) A method for in vitro molecular evolution of protein function

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application